Protagonist Therapeutics, Inc. (PTGX)

Compare

48.20

+1.32

+(2.82%)

At close: 4:00:00 PM EDT

47.49

-0.71

(-1.47%)

After hours: 5:21:55 PM EDT

Wall Street Analysts See a 27.36% Upside in Protagonist Therapeutics (PTGX): Can the Stock Really Move This High?

The consensus price target hints at a 27.4% upside potential for Protagonist Therapeutics (PTGX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks 8 days ago

PTGX
+2.82%
Analysts Mentions Growth Catalysts for Protagonist Therapeutics (PTGX) — Best Biotech Stock for 2025?

We recently published a list of Top 10 Trending Stocks as AI Hype Fades. In this article, we are going to take a look at where Protagonist Therapeutics, Inc. (NASDAQ:PTGX) stands against other top trending stocks as AI hype fades. The US stock market took a major hit recently due to tariff-related uncertainties and a […]

Insider Monkey 15 days ago

PTGX
+2.82%
Protagonist Therapeutics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025

Past Winners include Waymo, Nvidia, Duolingo, and Novo Nordisk, among others NEWARK, CA / ACCESS Newswire / March 18, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company"), a clinical-stage biopharmaceutical company pioneering the ...

ACCESS Newswire 15 days ago

PTGX
+2.82%
These 10 biotech companies are changing how we discover new drugs and treat complex diseases

The 10 most innovative biotech companies of 2025 are leveraging AI to find new drugs, match patients with the best treatments, and even support biodiversity research.

FastCompany 15 days ago

PTGX
+2.82%
TXG

WGSWW
Is Protagonist Therapeutics, Inc. (PTGX) the Best Healthcare Stock For Long-Term Investment?

We recently published a list of 10 Best Healthcare Stocks For Long-Term Investment. In this article, we are going to take a look at where Protagonist Therapeutics, Inc. (NASDAQ:PTGX) stands against other best healthcare stocks for long-term investment. Rising Healthcare Costs and the Impact of Tariffs on the US Industry In the US, healthcare expenditures […]

Insider Monkey 18 days ago

PTGX
+2.82%
Biotech Stock Roundup: TSVT Up on BMY Deal, PTGX Up on Data & More

TSVT and PTGX are in the spotlight this week following an acquisition agreement and study data, respectively.

Zacks 20 days ago

PTGX
+2.82%
GILD
Protagonist Therapeutics (PTGX) Upgraded to Buy: Here's Why

Protagonist Therapeutics (PTGX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks 21 days ago

PTGX
+2.82%
PTGX Up as J&J-Partnered Drug Meets Goal in Ulcerative Colitis Study

The phase IIb ANTHEM-UC study evaluating Protagonist and JNJ's icotrokinra for treating ulcerative colitis meets the primary endpoint.

Zacks 22 days ago

PTGX
+2.82%
JNJ

BMRN
Protagonist Therapeutics Soars as Icotrokinra Drives Breakthrough Success

PTGX Achieves First Profit in 2024 Amid Clinical Milestones and Financial Turnaround

GuruFocus.com 22 days ago

PTGX
+2.82%
JNJ
J&J and Protagonist’s icotrokinra scores in Phase IIb UC study

GlobalData predicts that icotrokinra will reach blockbuster status in 2029, with the drug forecast to generate sales of $2.19bn in 2030.

Clinical Trials Arena 22 days ago

JNJ

GLDAF

PTGX
+2.82%
Why Protagonist Therapeutics, Inc. (PTGX) Went Up on Monday

We recently compiled a list of the 10 Firms Buck Market Bloodbath on Monday. In this article, we are going to take a look at where Protagonist Therapeutics, Inc. (NASDAQ:PTGX) stands against the other stocks. The stock market suffered a bloodbath anew on Monday, with the Nasdaq plunging to its worst level in three years over concerns […]

Insider Monkey 22 days ago

PTGX
+2.82%
^GSPC
Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out

Protagonist Therapeutics broke out Monday after the company's drug topped its rival from Bristol in a psoriasis study.

Investor's Business Daily 23 days ago

BMY

CELG-RT

ABBV
Sector Update: Health Care Stocks Decline Late Afternoon

Health care stocks were lower late Monday afternoon, with the NYSE Health Care Index shedding 1.4% a

PREMIUM
MT Newswires 23 days ago

CKPT

MLYS

PTGX
+2.82%
Top Midday Gainers

Mineralys Therapeutics (MLYS) said Monday that lorundrostat met primary endpoints in phase 3 Launch-

PREMIUM
MT Newswires 23 days ago

MLYS

RDFN

PTGX
+2.82%
Protagonist Reports Positive Top Line Results From Phase 2b Study of Icotrokinra Showing Potential to Transform the Treatment Paradigm for Patients With Ulcerative Colitis

Clinical response rate of 63.5% and clinical remission rate of 30.2% achieved at Week 12 with the highest dose, which continued to improve through Week 28 All three doses met the primary endpoint of clinical response at Week 12, with a favorable safety ...

ACCESS Newswire 23 days ago

PTGX
+2.82%
Icotrokinra Clinical Study Results Demonstrate Its Potential to Shift Treatment Paradigm and Set a New Standard for Treatment in Plaque Psoriasis

Nearly half of patients with moderate-to-severe plaque psoriasis (PsO) treated with icotrokinra achieved completely clear skin (IGA 0) at Week 24 in Phase 3 ICONIC-LEAD study Topline results from Phase 3 ICONIC-ADVANCE 1&2studies show icotrokinra ...

ACCESS Newswire 25 days ago

PTGX
+2.82%
News Flash: 10 Analysts Think Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Earnings Are Under Threat

The latest analyst coverage could presage a bad day for Protagonist Therapeutics, Inc. ( NASDAQ:PTGX ), with the...

Simply Wall St. 30 days ago

PTGX
+2.82%
Takeda-Protagonist Therapeutics Partnered Investigational Drug Hits Primary Goal In Late-Stage Study In Patients With Type Of Blood Cancer

On Monday, Protagonist Therapeutics, Inc. (NASDAQ:PTGX) and Takeda Pharmaceutical Co Ltd (NYSE:TAK) released topline results for the Phase 3 VERIFY study of rusfertide for polycythemia vera. Polycythemia vera is a type of blood cancer. It causes your bone marrow to make too many red blood cells. Also Read: Neurocrine Obtains Exclusive Rights For Depression Drug, Takeda Reacquires Japan Rights The study met its primary endpoint and all four key secondary endpoints. Rusfertide is a first-in-class

Benzinga 30 days ago

PTGX
+2.82%
TAK
Takeda and Protagonist report topline outcomes from trial of rusfertide

The randomised Phase III trial met its primary endpoint.

Clinical Trials Arena 30 days ago

TAK

PTGX
+2.82%
Protagonist, Takeda Say Phase 3 Study of Rusfertide Meets Endpoints in Polycythemia Vera

Protagonist Therapeutics (PTGX) and Takeda (TAK) said Monday that a phase 3 study of investigational

PREMIUM
MT Newswires 30 days ago

TAK

PTGX
+2.82%

Performance Overview

Return	PTGX	S&P 500 (^GSPC)
YTD	+24.87%	-3.58%
1-Year	+72.20%	+8.94%
3-Year	+99.34%	+24.75%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Protagonist Therapeutics, Inc. (PTGX)

Wall Street Analysts See a 27.36% Upside in Protagonist Therapeutics (PTGX): Can the Stock Really Move This High?

Analysts Mentions Growth Catalysts for Protagonist Therapeutics (PTGX) — Best Biotech Stock for 2025?

Protagonist Therapeutics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025

These 10 biotech companies are changing how we discover new drugs and treat complex diseases

Is Protagonist Therapeutics, Inc. (PTGX) the Best Healthcare Stock For Long-Term Investment?

Biotech Stock Roundup: TSVT Up on BMY Deal, PTGX Up on Data & More

Protagonist Therapeutics (PTGX) Upgraded to Buy: Here's Why

PTGX Up as J&J-Partnered Drug Meets Goal in Ulcerative Colitis Study

Protagonist Therapeutics Soars as Icotrokinra Drives Breakthrough Success

J&J and Protagonist’s icotrokinra scores in Phase IIb UC study

Why Protagonist Therapeutics, Inc. (PTGX) Went Up on Monday

Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out

Sector Update: Health Care Stocks Decline Late Afternoon

Top Midday Gainers

Protagonist Reports Positive Top Line Results From Phase 2b Study of Icotrokinra Showing Potential to Transform the Treatment Paradigm for Patients With Ulcerative Colitis

Icotrokinra Clinical Study Results Demonstrate Its Potential to Shift Treatment Paradigm and Set a New Standard for Treatment in Plaque Psoriasis

News Flash: 10 Analysts Think Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Earnings Are Under Threat

Takeda-Protagonist Therapeutics Partnered Investigational Drug Hits Primary Goal In Late-Stage Study In Patients With Type Of Blood Cancer

Takeda and Protagonist report topline outcomes from trial of rusfertide

Protagonist, Takeda Say Phase 3 Study of Rusfertide Meets Endpoints in Polycythemia Vera

Performance Overview